WO2003057146A3 - Novel compositions and methods for cancer - Google Patents
Novel compositions and methods for cancer Download PDFInfo
- Publication number
- WO2003057146A3 WO2003057146A3 PCT/US2002/041414 US0241414W WO03057146A3 WO 2003057146 A3 WO2003057146 A3 WO 2003057146A3 US 0241414 W US0241414 W US 0241414W WO 03057146 A3 WO03057146 A3 WO 03057146A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- novel compositions
- cancer
- methods
- carcinomas
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003557505A JP2005514923A (en) | 2001-12-26 | 2002-12-26 | Novel compositions and methods for cancer |
CA002471840A CA2471840A1 (en) | 2001-12-26 | 2002-12-26 | Novel compositions and methods for cancer |
EP02806226A EP1509539A4 (en) | 2001-12-26 | 2002-12-26 | Novel compositions and methods for cancer |
AU2002367390A AU2002367390A1 (en) | 2001-12-26 | 2002-12-26 | Novel compositions and methods for cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/035,832 | 2001-12-26 | ||
US10/035,832 US7820447B2 (en) | 2000-12-22 | 2001-12-26 | Compositions and methods for cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003057146A2 WO2003057146A2 (en) | 2003-07-17 |
WO2003057146A3 true WO2003057146A3 (en) | 2004-12-29 |
Family
ID=21885043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/041414 WO2003057146A2 (en) | 2001-12-26 | 2002-12-26 | Novel compositions and methods for cancer |
Country Status (6)
Country | Link |
---|---|
US (1) | US7820447B2 (en) |
EP (2) | EP2034030A3 (en) |
JP (2) | JP2005514923A (en) |
AU (1) | AU2002367390A1 (en) |
CA (1) | CA2471840A1 (en) |
WO (1) | WO2003057146A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030087252A1 (en) * | 2000-12-22 | 2003-05-08 | Morris David W. | Novel compositions and methods in cancer associated with altered expression of PRDM11 |
US7700274B2 (en) * | 2000-12-22 | 2010-04-20 | Sagres Discovery, Inc. | Compositions and methods in cancer associated with altered expression of KCNJ9 |
US20060194265A1 (en) * | 2001-10-23 | 2006-08-31 | Morris David W | Novel therapeutic targets in cancer |
US20040126762A1 (en) * | 2002-12-17 | 2004-07-01 | Morris David W. | Novel compositions and methods in cancer |
WO2004016733A2 (en) | 2002-08-16 | 2004-02-26 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
CA2603780A1 (en) * | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics, Inc. | Sema4d in cancer diagnosis, detection and treatment |
FR2890859B1 (en) | 2005-09-21 | 2012-12-21 | Oreal | DOUBLE-STRANDED RNA OLIGONUCLEOTIDE INHIBITING TYROSINASE EXPRESSION |
EP1975228A1 (en) * | 2007-03-28 | 2008-10-01 | Fachhochschule Mannheim | Polynucleotides for enhancing expression of a polynucleotide of interest |
WO2009034661A1 (en) * | 2007-09-12 | 2009-03-19 | Toppan Printing Co., Ltd. | Method for diagnosis and induction of resistance to virus |
WO2009073478A2 (en) | 2007-11-30 | 2009-06-11 | Applied Genomics, Inc. | Tle3 as a marker for chemotherapy |
US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
BR112013027583A2 (en) * | 2011-04-28 | 2016-09-06 | Alexander Pearlman | genomic signatures of metastases in prostate cancer |
CA2872857A1 (en) * | 2011-05-10 | 2012-11-15 | Brunangelo Falini | Hairy cell leukemia biomarkers and methods of using same |
BR112015024752A2 (en) | 2013-03-27 | 2017-07-18 | Cedars Sinai Medical Center | mitigation and reversal of fibrosis and inflammation through inhibition of tl1a function and related signaling pathways |
EP4105236A1 (en) | 2013-07-19 | 2022-12-21 | Cedars-Sinai Medical Center | Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease |
US11186872B2 (en) | 2016-03-17 | 2021-11-30 | Cedars-Sinai Medical Center | Methods of diagnosing inflammatory bowel disease through RNASET2 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (en) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | blood substitute |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
DE3675588D1 (en) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE). |
WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
US5359100A (en) | 1987-10-15 | 1994-10-25 | Chiron Corporation | Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers |
US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
DE69008521T2 (en) | 1989-03-07 | 1994-10-20 | Genentech Inc | COVALENT CONJUGATES OF LIPIDS AND OLIGONUCLEOTIDS. |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
JPH0456210A (en) * | 1990-06-26 | 1992-02-24 | Mitsubishi Electric Corp | Electron beam exposure device |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5386023A (en) | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (en) | 1990-08-29 | 1997-12-16 | Genpharm Int | PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES. |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5644048A (en) | 1992-01-10 | 1997-07-01 | Isis Pharmaceuticals, Inc. | Process for preparing phosphorothioate oligonucleotides |
US5681697A (en) | 1993-12-08 | 1997-10-28 | Chiron Corporation | Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor |
US5637684A (en) | 1994-02-23 | 1997-06-10 | Isis Pharmaceuticals, Inc. | Phosphoramidate and phosphorothioamidate oligomeric compounds |
US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
US5759776A (en) | 1995-06-05 | 1998-06-02 | California Pacific Medical Center | Targets for breast cancer diagnosis and treatment |
AU725716C (en) | 1996-01-23 | 2003-02-20 | Board Of Trustees Of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
US5776683A (en) | 1996-07-11 | 1998-07-07 | California Pacific Medical Center | Methods for identifying genes amplified in cancer cells |
US5928870A (en) | 1997-06-16 | 1999-07-27 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
US6074825A (en) | 1997-07-31 | 2000-06-13 | Maine Medical Center | Stable encapsulated reference nucleic acid and method of making |
US6153441A (en) | 1998-02-17 | 2000-11-28 | Smithkline Beecham Corporation | Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof |
EP1358349A2 (en) | 2000-06-05 | 2003-11-05 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
WO2002022660A2 (en) | 2000-09-11 | 2002-03-21 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
JP2004537261A (en) | 2000-12-08 | 2004-12-16 | イプソゲン | Gene expression profiling of primary breast cancer using an array of candidate genes |
US20030216558A1 (en) | 2000-12-22 | 2003-11-20 | Morris David W. | Novel compositions and methods for cancer |
WO2003008583A2 (en) | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
NL1033850C2 (en) | 2007-05-15 | 2008-11-18 | 3Force B V | Burner system with premixed burners and flame transfer agents. |
WO2013037693A2 (en) | 2011-09-15 | 2013-03-21 | Convergent Information Technologies Gmbh | System and method for the automatic generation of robot programs |
EP2814652B1 (en) | 2012-02-13 | 2019-06-19 | Radius Engineering Inc. | Reusable cartridge for injection molding |
-
2001
- 2001-12-26 US US10/035,832 patent/US7820447B2/en not_active Expired - Fee Related
-
2002
- 2002-12-26 WO PCT/US2002/041414 patent/WO2003057146A2/en active Search and Examination
- 2002-12-26 EP EP08020946A patent/EP2034030A3/en not_active Withdrawn
- 2002-12-26 EP EP02806226A patent/EP1509539A4/en not_active Withdrawn
- 2002-12-26 CA CA002471840A patent/CA2471840A1/en not_active Abandoned
- 2002-12-26 JP JP2003557505A patent/JP2005514923A/en active Pending
- 2002-12-26 AU AU2002367390A patent/AU2002367390A1/en not_active Abandoned
-
2009
- 2009-06-01 JP JP2009132602A patent/JP2009195249A/en active Pending
Non-Patent Citations (2)
Title |
---|
DATABASE GENBANK [online] XP002991928, Database accession no. U78076 * |
LEE ET AL: "Cloning of mouse sepiapterin reductase gene and characterization of its promoter region", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1445, no. 1, 1999, pages 165 - 171, XP004275373 * |
Also Published As
Publication number | Publication date |
---|---|
CA2471840A1 (en) | 2003-07-17 |
JP2005514923A (en) | 2005-05-26 |
EP1509539A2 (en) | 2005-03-02 |
EP2034030A2 (en) | 2009-03-11 |
WO2003057146A2 (en) | 2003-07-17 |
EP1509539A4 (en) | 2006-05-17 |
JP2009195249A (en) | 2009-09-03 |
US7820447B2 (en) | 2010-10-26 |
US20070037145A1 (en) | 2007-02-15 |
EP2034030A3 (en) | 2009-07-22 |
AU2002367390A1 (en) | 2003-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003008583A3 (en) | Novel compositions and methods for cancer | |
EP2014669A3 (en) | Compositions and methods for cancer | |
WO2003045230A3 (en) | Novel compositions and methods for cancer | |
AU2003300368A1 (en) | Methods and compositions for the diagnosis, prognosis, and treatment of cancer | |
AU2002339865A1 (en) | Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors | |
EP1470146B8 (en) | Antibodies against the muc18 antigen | |
WO2004063355A3 (en) | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer | |
ZA200409492B (en) | Compositions and methods for the diagnosis and treatment of tumor. | |
AU2003254038A1 (en) | Glyconjugates comprising carbohydrate epitopes, methods for theirsynthesis, and their use for the treatment or prophylaxis of cancer | |
EP2764865A3 (en) | Cancer treatment | |
WO2003057146A3 (en) | Novel compositions and methods for cancer | |
MY136095A (en) | Use of human anti-ctla-4 antibodies for treatment of cancer | |
WO2004069152A3 (en) | Δ4,5 glycuronidase and uses thereof | |
WO2001017543A3 (en) | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer | |
IL173352A0 (en) | Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers | |
SG167670A1 (en) | Aminocyclohexyl ether compounds and uses thereof | |
AU2003297318A1 (en) | Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476. | |
WO2003053224A3 (en) | Novel compositions and methods for cancer | |
WO2002081745A3 (en) | Genes involved in osteogenesis, and methods of use | |
WO2002024867A3 (en) | Novel compositions and methods for lymphoma and leukemia | |
WO2003035837A3 (en) | Novel compositions and methods for cancer | |
WO2003045324A3 (en) | 14-methyl-epothilones | |
EP1551388A4 (en) | Compounds useful for the treatment of cancer, compositions thereof and methods therewith | |
AU2002219137A1 (en) | Diagnosis kit, dna chip, and methods for diagnosing or supervising the treatment of testicular cancer | |
WO2004047757A3 (en) | Diagnosing and treating hematopoietic cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003557505 Country of ref document: JP Ref document number: 2471840 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002367390 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002806226 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002806226 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |